Sugi Predict

Sugi Predict / Compounds / SCHEMBL10163505

SCHEMBL10163505

SCHEMBL10163505

CC(F)Oc1cccc(CNC(=O)c2cc(C(=O)NCc3ccc4oc(=O)n(C)c4c3)nc3c(F)cnn23)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 2/20 0.40
▸ ADAMTS4 O75173 1/20 0.40
▸ MMP3 P08254 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ ATM Q13315 1/20 0.38
▸ TP53 P04637 2/20 0.37
▸ IDO1 P14902 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ CLK1 P49759 1/20 0.36
▸ ROCK1 Q13464 2/20 0.36
▸ ROS1 P08922 1/20 0.36
▸ ALK Q9UM73 1/20 0.36
▸ ROCK2 O75116 2/20 0.35
▸ TNIK Q9UKE5 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ GPR55 Q9Y2T6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10163504 0.94 MMP13 (0.40) MMP13ADAMTS4MMP3LMNATP53
SCHEMBL13593081 0.93 MMP13 (0.38) MMP13ADAMTS4MMP3LMNAATM
SCHEMBL10163496 0.91 ADAMTS4 (0.43) MMP13ADAMTS4MMP3LMNAATM
SCHEMBL8229799 0.91 ROCK2 (0.44) MMP13ADAMTS4MMP3ROCK1ROCK2
SCHEMBL10163501 0.90 ALDH1A1 (0.38) MMP13ADAMTS4MMP3LMNAATM
SCHEMBL8226631 0.90 MMP13 (0.40) MMP13ADAMTS4MMP3LMNATP53
SCHEMBL8225568 0.90 MMP13 (0.43) MMP13ADAMTS4MMP3TP53IDO1
SCHEMBL10163488 0.89 MMP13 (0.44) MMP13ADAMTS4MMP3LMNATP53
SCHEMBL10163455 0.89 POLB (0.45) MMP13ADAMTS4MMP3LMNATP53
SCHEMBL8228206 0.89 MMP13 (0.42) MMP13ADAMTS4MMP3LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.